| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00259-013-2373-3 |
| P698 | PubMed publication ID | 23591953 |
| P50 | author | Valentina Ambrosini | Q37842637 |
| Cinzia Pettinato | Q48678270 | ||
| P2093 | author name string | Riccardo Schiavina | |
| Eugenio Brunocilla | |||
| Cristina Nanni | |||
| Giuseppe Martorana | |||
| Stefano Boschi | |||
| Stefano Fanti | |||
| P2860 | cites work | Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression | Q24654019 |
| Molecular preservation by extraction and fixation, mPREF: a method for small molecule biomarker analysis and histology on exactly the same tissue | Q31043717 | ||
| Detection of recurrent prostate carcinoma with anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT and 111In-capromab pendetide SPECT/CT | Q34995973 | ||
| Putative transport mechanism and intracellular fate of trans-1-amino-3-18F-fluorocyclobutanecarboxylic acid in human prostate cancer | Q38335459 | ||
| Regional distribution and kinetics of [18F]fluciclovine (anti-[18F]FACBC), a tracer of amino acid transport, in subjects with primary prostate cancer | Q39508939 | ||
| Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma | Q40186415 | ||
| [11C]choline positron emission tomography/computerized tomography to restage prostate cancer cases with biochemical failure after radical prostatectomy and no disease evidence on conventional imaging | Q42965590 | ||
| Improved synthesis of anti-[18F]FACBC: improved preparation of labeling precursor and automated radiosynthesis | Q44472753 | ||
| Biochemical failure does not predict overall survival after radical prostatectomy for localized prostate cancer: 10-year results | Q44644044 | ||
| Synthesis and evaluation of [18F]1-amino-3-fluorocyclobutane-1-carboxylic acid to image brain tumors | Q48279610 | ||
| Biodistribution and radiation dosimetry of the synthetic nonmetabolized amino acid analogue anti-18F-FACBC in humans. | Q51753150 | ||
| [Rational imaging in locally advanced prostate cancer]. | Q53394166 | ||
| [PET and PET/CT in relapsing prostate carcinoma]. | Q53518808 | ||
| Transport mechanisms of trans-1-amino-3-fluoro[1-14C]cyclobutanecarboxylic acid in prostate cancer cells | Q57759278 | ||
| P921 | main subject | patient | Q181600 |
| prostate cancer | Q181257 | ||
| P304 | page(s) | S11-7 | |
| P577 | publication date | 2013-04-17 | |
| P1433 | published in | European Journal of Nuclear Medicine and Molecular Imaging | Q15708890 |
| P1476 | title | Comparison of 18F-FACBC and 11C-choline PET/CT in patients with radically treated prostate cancer and biochemical relapse: preliminary results | |
| P478 | volume | 40 Suppl 1 |
| Q52984458 | (18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) versus (11)C-choline PET/CT in prostate cancer relapse: results of a prospective trial. |
| Q92128120 | 18F-fluciclovine PET CT detection of biochemical recurrent prostate cancer at specific PSA thresholds after definitive treatment |
| Q38983205 | Accumulation of trans-1-amino-3-[(18)F]fluorocyclobutanecarboxylic acid in prostate cancer due to androgen-induced expression of amino acid transporters |
| Q39041614 | Advances in Prostate Cancer Magnetic Resonance Imaging and Positron Emission Tomography-Computed Tomography for Staging and Radiotherapy Treatment Planning |
| Q34139498 | Anti-3-[(18)F]FACBC positron emission tomography-computerized tomography and (111)In-capromab pendetide single photon emission computerized tomography-computerized tomography for recurrent prostate carcinoma: results of a prospective clinical trial |
| Q37214430 | Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapy |
| Q34228828 | Comparative performance of PET tracers in biochemical recurrence of prostate cancer: a critical analysis of literature. |
| Q37350456 | Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer |
| Q48320897 | Diagnostic accuracy of C-11 choline and C-11 acetate for lymph node staging in patients with bladder cancer: a systematic review and meta-analysis. |
| Q38924532 | Diagnostic performance and safety of NMK36 (trans-1-amino-3-[18F]fluorocyclobutanecarboxylic acid)-PET/CT in primary prostate cancer: multicenter Phase IIb clinical trial |
| Q51035093 | Economic evaluation of diagnostic localization following biochemical prostate cancer recurrence. |
| Q38599162 | Emerging treatments for recurrent prostate cancer |
| Q86492358 | First imaging results of an intraindividual comparison of (11)C-acetate and (18)F-fluorocholine PET/CT in patients with prostate cancer at early biochemical first or second relapse after prostatectomy or radiotherapy |
| Q41694062 | Fluorine-18 labeled amino acids for tumor PET/CT imaging |
| Q38321182 | Imaging biomarkers in prostate cancer: role of PET/CT and MRI. |
| Q56358992 | Imaging of Prostate Cancer Using Fluciclovine |
| Q38852724 | Imaging of local recurrence in prostate cancer |
| Q38823996 | Imaging oligometastatic cancer before local treatment |
| Q52653486 | Imaging the High-risk Prostate Cancer Patient: Current and Future Approaches to Staging. |
| Q56961941 | Interpretation of 11C-choline PET/CT for the diagnosis of local relapse in radically treated prostate cancer |
| Q38877792 | Localizing sites of disease in patients with rising serum prostate-specific antigen up to 1ng/ml following prostatectomy: How much information can conventional imaging provide? |
| Q38379159 | Lymph node staging in prostate cancer. |
| Q37550399 | Molecular imaging of urogenital diseases |
| Q38767020 | NMR-based metabolomics of prostate cancer: a protagonist in clinical diagnostics |
| Q38268168 | Nuclear medicine in urological cancers: what is new? |
| Q39003086 | PET Tracers Beyond FDG in Prostate Cancer. |
| Q38831029 | PET imaging of recurrent and metastatic prostate cancer with novel tracers |
| Q42388521 | PET/CT is a cost-effective tool against cancer: synergy supersedes singularity |
| Q41862609 | Phase IIa Clinical Trial of Trans-1-Amino-3-(18)F-Fluoro-Cyclobutane Carboxylic Acid in Metastatic Prostate Cancer |
| Q39242936 | Positron emission tomography (PET) imaging of prostate cancer with a gastrin releasing peptide receptor antagonist--from mice to men. |
| Q33890153 | Positron emission tomography (PET) in primary prostate cancer staging and risk assessment |
| Q43636204 | Potential of PET/MRI for diagnosis of prostate cancer |
| Q40741628 | Preliminary clinical experience of trans-1-Amino-3-(18)F-fluorocyclobutanecarboxylic Acid (anti-(18)F-FACBC) PET/CT imaging in prostate cancer patients |
| Q45309621 | Prostate cancer: lymph node metastases: not always the same prognosis |
| Q39014453 | Reduced 64Cu uptake and tumor growth inhibition by knockdown of human copper transporter 1 in xenograft mouse model of prostate cancer. |
| Q36839766 | Reproducibility and reliability of anti-3-[¹⁸F]FACBC uptake measurements in background structures and malignant lesions on follow-up PET-CT in prostate carcinoma: an exploratory analysis |
| Q47123424 | Saving costs in cancer patient management through molecular imaging |
| Q28074669 | Target Definition in Salvage Radiotherapy for Recurrent Prostate Cancer: The Role of Advanced Molecular Imaging |
| Q57109624 | The utility of PET-based imaging for prostate cancer biochemical recurrence: a systematic review and meta-analysis |
| Q38439189 | The value of anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT in the diagnosis of recurrent prostate carcinoma: a meta-analysis |
| Q94570850 | Understanding and Improving 18F-Fluciclovine PET/CT Reports: A Guide for Physicians Treating Patients with Biochemical Recurrence of Prostate Cancer |
| Q33625389 | Update on advances in molecular PET in urological oncology |
| Q53094162 | Writing PET into existence. |
| Q87610913 | [Molecular multimodal hybrid imaging in prostate and bladder cancer] |
Search more.